Company Profile

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

Employees

Sector

Biotechnology & Medical Research

More about the company

20-01-29	Achillion Pharmaceuticals, Inc.(NasdaqGS:ACHN) dropped from S&P Global BMI Index	CI
20-01-29	Achillion Pharmaceuticals, Inc.(NasdaqGM:ACHN) dropped from S&P TMI Index	CI
20-01-29	Achillion Pharmaceuticals, Inc.(NasdaqGM:ACHN) dropped from S&P Biotechnology Select Industry Index	CI
20-01-28	Achillion Pharmaceuticals, Inc. Announces Management Changes	CI
20-01-28	Achillion Pharmaceuticals, Inc.(NasdaqGS:ACHN) dropped from NASDAQ Composite Index	CI
20-01-28	Achillion Pharmaceuticals, Inc.(NasdaqGS:ACHN) dropped from NASDAQ Biotechnology Index	CI
20-01-27	Alexion Pharmaceuticals, Inc. completed the acquisition of Achillion Pharmaceuticals, Inc..	CI
19-12-09	Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting	CI
19-11-19	European Medicines Agency Grants Achillion PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor	CI
19-11-11	Achillion Pharmaceuticals, Inc. Announces Clearance of Investigational New Drug Application for ACH-5228	CI
19-11-07	Achillion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
19-10-15	Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire Achillion Pharmaceuticals, Inc. for approximately $880 million.	CI
19-09-25	Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria	CI

20-08-18	Achillion Pharmaceuticals : Ahold Delhaize share buyback update August 18, 2020	PU
20-08-11	Achillion Pharmaceuticals : Ahold Delhaize share buyback update August 11, 2020	PU
20-08-05	Achillion Pharmaceuticals : AD Q2 2020 results	PU
20-08-05	Achillion Pharmaceuticals : Ahold Delhaize Q2 2020 results	PU
20-08-04	Achillion Pharmaceuticals : Ahold Delhaize Q2 results conference call and webcast	PU

15-02-09	USA-Les valeurs à suivre à Wall Street
14-06-10	Wall Street consolide à ses niveaux record
14-06-10	Dow Jones Industrial Average : Wall Street finit sur une note stable
14-06-10	Achillion Pharmaceuticals : Les valeurs à suivre à Wall Street
14-06-10	USA-Les valeurs à suivre à Wall Street (actualisé)

Manager	Title	Age	Since
Milind Deshpande CEO	Chief Executive Officer	69	2013-05-27
Michael Ira Kenneth Elloian TRE	Treasurer	54	2020-01-27

Date	Insider	Type	Main position	Quantity	% Market Cap.
20-01-27	Paul Firuta	Issuer sale	Chief Operating Officer	600,000	0.4283%
20-01-27	Brian DiDonato	Issuer sale	Chief Financial Officer	700,000	0.4997%
20-01-27	David Scheer	Issuer sale	Chairman	319,764	0.2283%

Achillion Pharmaceuticals, Inc. Stock

Stocks

US00448Q2012

Biotechnology & Medical Research

Latest news : Achillion Pharmaceuticals, Inc.

Press Releases: Achillion Pharmaceuticals, Inc.

News in other languages: Achillion Pharmaceuticals, Inc.

Managers and Directors: Achillion Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACHILLION PHARMACEUTICALS, INC.	-.--%	+9.21%	-	-	947M
ARGENX SE	-2.86%	-0.26%	+51.45%	+110.98%	56.42B
WUXI APPTEC CO., LTD.	-0.34%	+3.51%	+45.55%	+40.16%	44.54B
BIONTECH SE	+0.29%	+6.20%	-14.80%	-19.65%	22.9B
INSMED INCORPORATED	-0.40%	+3.49%	-1.29%	+387.06%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	-2.26%	+0.87%	+13.96%	-36.35%	16.4B
GENMAB A/S	-1.54%	-1.06%	+7.63%	-39.28%	15.4B
EXELIXIS, INC.	-0.24%	+2.44%	+27.43%	+177.49%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.10%	+5.94%	+15.09%	-	12.36B
PHARMAESSENTIA CORPORATION	+0.32%	+2.81%	+96.37%	+213.49%	11.15B
Average	-0.92%	+1.51%	+26.82%	+104.24%	23.75B
Weighted average by Cap.	-1.24%	+1.93%	+30.60%	+96.14%